Immunocore Holdings plc, a UK-based biopharmaceutical company specializing in T-cell receptor immunotherapy, has experienced steady revenue growth alongside persistent operating losses. The company benefits from strong liquidity and UK tax incentives but faces significant constraints from international regulatory complexities, geopolitical uncertainties including trade tariffs, and ongoing R&D costs. Future growth hinges on clinical development milestones and commercialization efforts, while capital allocation currently prioritizes reinvestment over shareholder returns.